![]() Silvec Biologics Silvec Biologics is a biotechnology company that specializes in vaccinating trees using RNA therapy. | ![]() Biohaven Pharmaceutical Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system. | ![]() Walvax Biotechnology Walvax Biotechnology (also known as Yunnan Watson Biotechnology, 云南沃森生物技术股份有限公司) is a company that is engaged in the research and development, production, and sales of human vaccines and biotechnology drugs. | ![]() Relay Therapeutics Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities. | |
Founding Date | Founding Date 2019 | Founding Date 2014 | Founding Date 2001 | Founding Date 2016 |
Type | Type Private | Type Subsidiary | Type Public | Type Public |
Tags | ||||
Locations | Locations Gaithersburg, US HQ | Locations New Haven, US HQ | Locations Kunming, CN HQ | Locations Cambridge, US HQ |
Employees | Employees 129% increase | Employees 4343% increase | Employees 2,388 | Employees 2724% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 3.3 b | Valuation ($) 958.5 m |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) ¥2.4b (FY, 2025) | Revenue (est.) $15.4m (FY, 2025) |
Net income | Net income N/A | Net income N/A | Net income ¥125.2m (FY, 2025) | Net income ($276.5m) (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 80m | Total funding raised $ 72.8m | Total funding raised $ 520m |

Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.
View company
Walvax Biotechnology (also known as Yunnan Watson Biotechnology, 云南沃森生物技术股份有限公司) is a company that is engaged in the research and development, production, and sales of human vaccines and biotechnology drugs.
View company
Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities.
View company